The New Clinical Trial Regulation - by Compliance Global Inc.
This webinar explains why it is important to know the new procedures for approval of clinical trials to avoid delays and minimize the time for approval. Know the single authorization procedure for clinical trials which will be introduced and performed electronically via a new EU portal.
New Hyde Park, NY, September 03, 2015 --(PR.com)-- Overview
On 16 April 2014 the new Regulation EU No 536/2014 of the European Parliament and of the Council on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC was adopted, and published in the Official Journal on 27 May 2014 (the "Clinical Trials Regulation").
Especially the procedure for assessment and approval of multinational clinical trial authorisation applications will change. A single authorisation procedure for clinical trials will be introduced that will be performed electronically via a new EU portal.
The Regulation will ensure that, no matter where a clinical trial is being performed, the fundamental rules for the protection of subjects are applied. It therefore includes rules for clinical trials which are conducted outside the EU but referred to in a clinical trial application within the EU. For such trials, the rules call for compliance with regulatory requirements at least equivalent to those in the EU, including rules on transparency
Why Should You Attend:
It is important to know the new procedures for approval of clinical trials to avoid delays and minimize the time for approval.
In the current situation, a common protocol is proposed in all EU Member States that participate in a clinical trial but requests for amendments may result in country-specific changes that require subsequent amendments in other countries to maintain a common protocol.
In the Webinar it will be explained how in the new procedure this problem will be avoided.
The Webinar will also discuss important changes with regard to the protection of subjects and give a detailed overview of the new procedure. A detailed knowledge of the new procedure are all key to personal responsible for clinical trial applications.
Additionally, the new Regulation will affect how the conduct of a clinical trial is managed after approval has been granted. New provisions for public access to an EU clinical trials database will enforce disclosure of clinical trials data and information.
Areas Covered in this Webinar:
The webinar will start with a discussion of the disadvantages of the current situation.
An overview of the Clinical Trials Regulation and the scope of the regulation will be provided. In particular the following points will be addressed:
A streamlined application procedure via a single entry point;
An EU portal and database, for all clinical trials conducted in Europe. Registration via the portal will be a prerequisite for the assessment of any application;
A single authorisation procedure for all clinical trials, allowing a faster and thorough assessment of an application by all Member States concerned, and ensuring one single assessment outcome and authorisation per Member State. Ethics committees will be involved in the assessment of clinical trials application. However, as with the current situation, their responsibilities and detailed composition will be determined independently by each EU country. In this way the different traditions in the various Member States are respected
The extension of the tacit agreement principle to the whole authorisation process which will give sponsors and researchers, in particular SMEs and academics, more legal certainty. The tacit agreement is to alleviate an unnecessary and frustrating restriction that trial sponsors face under the current rules. It is important, however, to emphasise that Member States will always have the possibility to stop any clinical trial, which they consider could endanger the heath of the participants
Strengthened transparency for clinical trials data. Transparency on the conduct and results of clinical trials has several benefits, and the Regulation strengthens the rules accordingly Transparency avoids redundancy and duplication. It ensures that even clinical trials with unfavourable results are made public, thereby avoiding 'publication bias'. Finally, transparency gives patients the possibility to find out about on-going clinical trials in which they may wish to participate
The timelines for implementation will be described.
Learning Objectives:
Knowledge of the new Regulation
Knowledge of the impact of the new Regulation for the industry
Who Will Benefit:
Regulatory Affairs Personnel
CRA’s
Clinical Operations Personnel
Personnel in the pharmaceutical and biotech industries who need a thorough understanding of the regulatory issues involved in the development of new medicinal products within the European Union
Individuals who are seeking to update their knowledge of recent regulatory changes and their impact on product development
Level:
Intermediate
For more information, please visit https://www.complianceglobal.us/product/700185
About Compliance Global Inc:
Compliance Global Inc; is a training (webinar) organization based in New Hyde Park, New York, providing world-class compliance trainings and online webinars by leveraging a pool of experienced speakers / consultants in the Pharmaceutical, Bio-Technology, Medical Devices, Clinical Compliance, FDA Compliance, Healthcare, BFSI, Life Science & HR streams for improving the knowledge base of the customers. Our trainings are contemporary, simple and cost-effective with easy access and great delivery experience. Compliance Global is a multifaceted entity, an absolute knowledge repository.
Email: referrals@complianceglobal.us
Toll Free: +1-844-746-4244
Tel: +1-516-900-5515
On 16 April 2014 the new Regulation EU No 536/2014 of the European Parliament and of the Council on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC was adopted, and published in the Official Journal on 27 May 2014 (the "Clinical Trials Regulation").
Especially the procedure for assessment and approval of multinational clinical trial authorisation applications will change. A single authorisation procedure for clinical trials will be introduced that will be performed electronically via a new EU portal.
The Regulation will ensure that, no matter where a clinical trial is being performed, the fundamental rules for the protection of subjects are applied. It therefore includes rules for clinical trials which are conducted outside the EU but referred to in a clinical trial application within the EU. For such trials, the rules call for compliance with regulatory requirements at least equivalent to those in the EU, including rules on transparency
Why Should You Attend:
It is important to know the new procedures for approval of clinical trials to avoid delays and minimize the time for approval.
In the current situation, a common protocol is proposed in all EU Member States that participate in a clinical trial but requests for amendments may result in country-specific changes that require subsequent amendments in other countries to maintain a common protocol.
In the Webinar it will be explained how in the new procedure this problem will be avoided.
The Webinar will also discuss important changes with regard to the protection of subjects and give a detailed overview of the new procedure. A detailed knowledge of the new procedure are all key to personal responsible for clinical trial applications.
Additionally, the new Regulation will affect how the conduct of a clinical trial is managed after approval has been granted. New provisions for public access to an EU clinical trials database will enforce disclosure of clinical trials data and information.
Areas Covered in this Webinar:
The webinar will start with a discussion of the disadvantages of the current situation.
An overview of the Clinical Trials Regulation and the scope of the regulation will be provided. In particular the following points will be addressed:
A streamlined application procedure via a single entry point;
An EU portal and database, for all clinical trials conducted in Europe. Registration via the portal will be a prerequisite for the assessment of any application;
A single authorisation procedure for all clinical trials, allowing a faster and thorough assessment of an application by all Member States concerned, and ensuring one single assessment outcome and authorisation per Member State. Ethics committees will be involved in the assessment of clinical trials application. However, as with the current situation, their responsibilities and detailed composition will be determined independently by each EU country. In this way the different traditions in the various Member States are respected
The extension of the tacit agreement principle to the whole authorisation process which will give sponsors and researchers, in particular SMEs and academics, more legal certainty. The tacit agreement is to alleviate an unnecessary and frustrating restriction that trial sponsors face under the current rules. It is important, however, to emphasise that Member States will always have the possibility to stop any clinical trial, which they consider could endanger the heath of the participants
Strengthened transparency for clinical trials data. Transparency on the conduct and results of clinical trials has several benefits, and the Regulation strengthens the rules accordingly Transparency avoids redundancy and duplication. It ensures that even clinical trials with unfavourable results are made public, thereby avoiding 'publication bias'. Finally, transparency gives patients the possibility to find out about on-going clinical trials in which they may wish to participate
The timelines for implementation will be described.
Learning Objectives:
Knowledge of the new Regulation
Knowledge of the impact of the new Regulation for the industry
Who Will Benefit:
Regulatory Affairs Personnel
CRA’s
Clinical Operations Personnel
Personnel in the pharmaceutical and biotech industries who need a thorough understanding of the regulatory issues involved in the development of new medicinal products within the European Union
Individuals who are seeking to update their knowledge of recent regulatory changes and their impact on product development
Level:
Intermediate
For more information, please visit https://www.complianceglobal.us/product/700185
About Compliance Global Inc:
Compliance Global Inc; is a training (webinar) organization based in New Hyde Park, New York, providing world-class compliance trainings and online webinars by leveraging a pool of experienced speakers / consultants in the Pharmaceutical, Bio-Technology, Medical Devices, Clinical Compliance, FDA Compliance, Healthcare, BFSI, Life Science & HR streams for improving the knowledge base of the customers. Our trainings are contemporary, simple and cost-effective with easy access and great delivery experience. Compliance Global is a multifaceted entity, an absolute knowledge repository.
Email: referrals@complianceglobal.us
Toll Free: +1-844-746-4244
Tel: +1-516-900-5515
Contact
Compliance Global Inc.
Roger Davis
+1-516-900-5515
https://www.complianceglobal.us/product/700185
Email: support@complianceglobal.us
Toll Free: +1-844-746-4244
Tel: +1-516-900-5515
Fax: +1-516-900-5510
Roger Davis
+1-516-900-5515
https://www.complianceglobal.us/product/700185
Email: support@complianceglobal.us
Toll Free: +1-844-746-4244
Tel: +1-516-900-5515
Fax: +1-516-900-5510
Contact
Categories